



Comoros

African Region



Based on 2015 reported data



I. Epidemiological profile

| Population (UN) | 2016 | % | Parasites and vectors | |
|--|---------|----|---|---|
| High transmission (> 1 case per 1000 population) | 379,000 | 48 | Plasmodium species: | <i>P. falciparum</i> (100%), <i>P. vivax</i> (0%) |
| Low transmission (0-1 cases per 1000 population) | 417,000 | 52 | Major anopheles species: | <i>An. gambiae</i> , <i>An. funestus</i> |
| Malaria-free (0 cases) | - | - | Reported confirmed cases (health facility): | 1,066 Estimated cases: 1100 |
| Total | 795,600 | - | Confirmed cases at community level: | 77 |
| | | | Reported deaths: | 0 Estimated deaths: ≤ 10 |



II. Intervention policies and strategies

| Intervention | Policies/strategies | Yes/No | Adopted | Antimalarial treatment policy | Medicine | Year adopted | | | | | |
|---|--|-----------|---------|---|---------------------------|--------------|--------|-----|--------------|-------------------------|----------------------|
| ITN | ITNs/ LLINs distributed free of charge | Yes | 2005 | First-line treatment of unconfirmed malaria | AL | 2003 | | | | | |
| | ITNs/ LLINs distributed to all age groups | Yes | 2010 | First-line treatment of <i>P. falciparum</i> | AL | 2003 | | | | | |
| IRS | IRS is recommended | Yes | 2010 | Treatment failure of <i>P. falciparum</i> | QN | 2003 | | | | | |
| | DDT is authorized for IRS | Yes | - | Treatment of severe malaria | QN | 2003 | | | | | |
| Larval control | Use of larval control recommended | No | - | Treatment of <i>P. vivax</i> | - | - | | | | | |
| IPT | IPT used to prevent malaria during pregnancy | Yes | 2004 | Dosage of Primaquine for radical treatment of <i>P. vivax</i> | - | - | | | | | |
| Diagnosis | Patients of all ages should receive diagnostic test | Yes | 1997 | Type of RDT used | P.f + all species (Combo) | | | | | | |
| | Malaria diagnosis is free of charge in the public sector | Yes | 2011 | | | | | | | | |
| Treatment | ACT is free of charge for all ages in public sector | Yes | 2010 | Therapeutic efficacy tests (clinical and parasitological failure, %) | | | | | | | |
| | The sale of oral artemisinin-based monotherapies (oAMTs) | Is banned | 2005 | Medicine | Year(s) | Min | Median | Max | Follow-up | No. of studies | Species |
| | Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i> | Yes | 2016 | AL | 2011-2013 | 0 | 0 | 2.5 | 28 days | 10 | <i>P. falciparum</i> |
| | Primaquine is used for radical treatment of <i>P. vivax</i> | No | - | Insecticide resistance tests (mosquito mortality, %) | | | | | | | |
| | G6PD test is a requirement before treatment with primaquine | No | - | Insecticide class | Years | Min | Mean | Max | No. of sites | Species | |
| | Directly observed treatment with primaquine is undertaken | No | - | Pyrethroids | 2014-2015 | 1 | 1 | 1 | 6 | <i>An. gambiae s.l.</i> | |
| System for monitoring adverse reactions to antimalarials exists | No | - | | | | | | | | | |
| Surveillance | ACD for case investigation (reactive) | Yes | 2013 | | | | | | | | |
| | ACD of febrile cases at community level (pro-active) | No | - | | | | | | | | |
| | Mass screening is undertaken | No | 2010 | | | | | | | | |
| | Uncomplicated <i>P. falciparum</i> cases routinely admitted | Yes | - | | | | | | | | |
| | Uncomplicated <i>P. vivax</i> cases routinely admitted | No | - | | | | | | | | |
| | Foci and case investigation undertaken | - | - | | | | | | | | |
| Case reporting from private sector is mandatory | Yes | 2010 | | | | | | | | | |

III. Financing



IV. Coverage



V. Impact

